{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:45:16Z","timestamp":1788021916517,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103475"],"award-info":[{"award-number":["82103475"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2024206056"],"award-info":[{"award-number":["H2024206056"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2023307028"],"award-info":[{"award-number":["H2023307028"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Medical Science Research Project of Hebei Provincial Health Commission","award":["20240370"],"award-info":[{"award-number":["20240370"]}]},{"name":"Hebei Province Medical Adaptation Technology Tracking Project","award":["GZ2024002"],"award-info":[{"award-number":["GZ2024002"]}]},{"name":"Hebei Province Government-Funded Clinical Medicine Excellent Talent Training Program","award":["ZF2025013"],"award-info":[{"award-number":["ZF2025013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40256-025-00738-9","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T01:46:20Z","timestamp":1749519980000},"page":"655-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations"],"prefix":"10.1007","volume":"25","author":[{"given":"Yihan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"22","key":"738_CR1","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.117.032380","volume":"137","author":"Z Wang","year":"2018","unstructured":"Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China hypertension survey, 2012\u20132015. Circulation. 2018;137(22):2344\u201356.","journal-title":"Circulation"},{"issue":"34","key":"738_CR2","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1093\/eurheartj\/ehab454","volume":"42","author":"MS Kim","year":"2021","unstructured":"Kim MS, Kim WJ, Khera AV, et al. Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies. Eur Heart J. 2021;42(34):3388\u2013403.","journal-title":"Eur Heart J"},{"issue":"11","key":"738_CR3","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00198-024-07227-w","volume":"35","author":"F Armutcu","year":"2024","unstructured":"Armutcu F, McCloskey E. Insulin resistance, bone health, and fracture risk. Osteoporosis Int. 2024;35(11):1909\u201317.","journal-title":"Osteoporosis Int"},{"issue":"12","key":"738_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jama.2024.2252","volume":"331","author":"D Mozaffarian","year":"2024","unstructured":"Mozaffarian D. GLP-1 agonists for obesity\u2014a new recipe for success? JAMA. 2024;331(12):1007\u20138.","journal-title":"JAMA"},{"issue":"2","key":"738_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258\u201366.","journal-title":"Diabetes Care"},{"issue":"5","key":"738_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"738_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"738_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100\u20139.","journal-title":"Diabetes Metab"},{"issue":"10278","key":"738_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England). 2021;397(10278):971\u201384.","journal-title":"Lancet (London, England)"},{"issue":"10","key":"738_CR10","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391.","journal-title":"Nat Med"},{"issue":"3","key":"738_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193\u2013206.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"738_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"15","key":"738_CR13","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407.","journal-title":"N Engl J Med"},{"issue":"11","key":"738_CR14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"738_CR15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000535198","volume":"17","author":"B McGowan","year":"2024","unstructured":"McGowan B, Bruun JM, Capehorn M, et al. STEP 10 trial: semaglutide 2.4\u00a0mg provided a superior reduction vs placebo in body weight and reversion to normoglycaemia in participants with obesity and prediabetes. Obes Facts. 2024;17:72\u20134.","journal-title":"Obes Facts"},{"issue":"3","key":"738_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","volume":"12","author":"Y Mu","year":"2024","unstructured":"Mu Y, Bao X, Eliaschewitz FG, et al. Efficacy and safety of once weekly semaglutide 2\u00b74 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024;12(3):184\u201395.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"738_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"738_CR18","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"HW Rodbard","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"738_CR19","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity the STEP 4 randomized clinical trial. JAMA J Am Med Assoc. 2021;325(14):1414\u201325.","journal-title":"JAMA J Am Med Assoc"},{"issue":"2","key":"738_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350.","journal-title":"JAMA"},{"issue":"1","key":"738_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/dom.15287","volume":"26","author":"S Sivalingam","year":"2024","unstructured":"Sivalingam S, Wasehuus VS, Rotbain Curovic V, et al. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: a randomized and placebo-controlled study. Diabetes Obes Metab. 2024;26(1):54\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"738_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"738_CR23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Butler J, Borlaug BA, et al. Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials. J Am Coll Cardiol. 2024;84(9):773\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"738_CR24","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"11","key":"738_CR25","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"5","key":"738_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356\u201367.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"738_CR27","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1007\/s00125-018-4644-9","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, Mazer CD, Fitchett D, et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME\u00ae randomised trial. Diabetologia. 2018;61(8):1712\u201323.","journal-title":"Diabetologia"},{"key":"738_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s12325-024-03002-9","volume":"42","author":"S Khare","year":"2024","unstructured":"Khare S, Osumili B, Debackere N, et al. Dosing patterns of dulaglutide and semaglutide in patients with type 2 diabetes mellitus in France and Italy: a retrospective cohort study. Adv Ther. 2024;42:174\u201392.","journal-title":"Adv Ther"},{"issue":"9","key":"738_CR29","first-page":"891","volume":"376","author":"TC Williams","year":"2017","unstructured":"Williams TC, Stewart E. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017;376(9):891.","journal-title":"N Engl J Med"},{"key":"738_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.810105","volume":"8","author":"M Huang","year":"2021","unstructured":"Huang M, Long L, Tan L, et al. Isolated diastolic hypertension and risk of cardiovascular events: a systematic review and meta-analysis of cohort studies with 489,814 participants. Front Cardiovasc Med. 2021;8: 810105.","journal-title":"Front Cardiovasc Med"},{"issue":"19","key":"738_CR31","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1056\/NEJMc1902837","volume":"380","author":"P Baglioni","year":"2019","unstructured":"Baglioni P. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(19):1880\u20131.","journal-title":"N Engl J Med"},{"issue":"24","key":"738_CR32","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"7","key":"738_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015323","volume":"9","author":"M Hu","year":"2020","unstructured":"Hu M, Cai X, Yang W, Zhang S, Nie L, Ji L. Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: a meta-analysis. J Am Heart Assoc. 2020;9(7): e015323.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"738_CR34","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12020-023-03636-9","volume":"83","author":"W Wu","year":"2024","unstructured":"Wu W, Tong HM, Li YS, Cui J. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis. Endocrine. 2024;83(3):571\u201384.","journal-title":"Endocrine"},{"issue":"38","key":"738_CR35","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","volume":"45","author":"C Kennedy","year":"2024","unstructured":"Kennedy C, Hayes P, Cicero AFG, et al. Semaglutide and blood pressure: an individual patient data meta-analysis. Eur Heart J. 2024;45(38):4124\u201334.","journal-title":"Eur Heart J"},{"key":"738_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40618-024-02459-3","volume":"48","author":"M Ala","year":"2024","unstructured":"Ala M, Moheb AM. The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression. J Endocrinol Investig. 2024;48:283\u201394.","journal-title":"J Endocrinol Investig"},{"issue":"6","key":"738_CR37","doi-asserted-by":"publisher","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","volume":"287","author":"T Nystr\u00f6m","year":"2004","unstructured":"Nystr\u00f6m T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209\u201315.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"738_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.101922","volume":"46","author":"PH Reis-Barbosa","year":"2022","unstructured":"Reis-Barbosa PH, Marcondes-de-Castro IA, Marinho TS, Aguila MB, Mandarim-de-Lacerda CA. The mTORC1\/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice. Clin Res Hepatol Gastroenterol. 2022;46(6): 101922.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"738_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116776","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi H, Sathyapalan T, Sahebkar A. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci. 2019;234: 116776.","journal-title":"Life Sci"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00738-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00738-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00738-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:55:05Z","timestamp":1757184905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00738-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00738-9","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"25 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the National Natural Science Foundation of China (82103475), Hebei Province Natural Science Foundation (H2023307028, H2024206056), the Medical Science Research Project of Hebei Provincial Health Commission (20240370), Hebei Province Medical Adaptation Technology Tracking Project (GZ2024002), and Hebei Province Government-Funded Clinical Medicine Excellent Talent Training Program (ZF2025013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yihan Li, Kefan Xue, Rui Hu, Xiao Hu, Ran Guo, Hongxia Guo, and Gang Li declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"YL: Conceptualization; methodology; software; investigation; formal analysis; writing \u2013 original draft. KX: Data curation; writing \u2013 original draft. RH: Visualization; investigation. XH: Resources; supervision. RG: Software; validation. HG: Visualization; writing \u2013 review and editing. GL: Conceptualization; funding acquisition; resources; supervision; writing \u2013 review and editing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}